Traditional antibody discovery methods often struggle with complex targets, low hit rates, and inefficient lead optimization, resulting in delays and increased costs in developing effective antibody-based therapeutics. Many promising drug targets, particularly complex transmembrane proteins, remain inaccessible to conventional antibody discovery approaches.

AbCellera is a biotechnology company focused on developing antibody-based therapies by integrating advanced technologies across computation, engineering, and biology. The company leverages a single-cell screening platform to deeply search natural immune responses and identify rare, potent antibodies against challenging disease targets. By combining high-throughput screening, microfluidics, machine learning, and protein engineering, AbCellera aims to accelerate the discovery and development of differentiated antibody therapeutics. Their integrated platform spans from target selection and antibody discovery to preclinical development and clinical manufacturing, enabling efficient progression of candidates towards clinical studies.

Proprietary single-cell screening technology for identifying rare and diverse antibodies

High-throughput microfluidic devices for isolating and screening thousands of single cells

Advanced immunization strategies for eliciting robust immune responses against difficult targets

Capabilities for generating and characterizing recombinant soluble and membrane proteins

Protein engineering capabilities for optimizing antibody sequences and formats, including bispecifics and T-cell engagers

In-house clinical manufacturing facility for GMP cell banking and drug substance production

Integrated computational tools and machine learning models for antibody selection and optimization

AbCellera's primary focus is on developing its own pipeline of antibody therapeutics for unmet medical needs, with a focus on autoimmunity, endocrine and metabolic conditions, and oncology.